ARTICLE | Company News
Topotarget, Novartis deal
March 19, 2007 7:00 AM UTC
TOPO exercised its option from NVS to an exclusive, worldwide license to develop and commercialize Zemab to treat cancer. The option was granted in a 2003 deal between NVS and G2M Cancer Drugs AG, wh...